Tumour necrosis factor inhibitors: maximizing patient safety

Rheumatology (Oxford). 2003 Jan;42(1):188-9. doi: 10.1093/rheumatology/keg046.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Etanercept
  • Humans
  • Immunoglobulin G / adverse effects*
  • Immunosuppressive Agents / adverse effects*
  • Infections / etiology*
  • Infliximab
  • Receptors, Tumor Necrosis Factor
  • Safety Management
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Etanercept